John D. Diekman

Ingenuity Systems, Inc. provides intuitive web-based applications for quickly analyzing and accurately interpreting the biological meaning of genomics data. The company was founded in 1998 and is headquartered in Redwood City, CA.

Antipodean Pharmaceuticals, Inc. manufactures pharmaceutical products and provides pre clinical services. Its product MitoQ, which blocks mitochondrial oxidative damage and prevents cell death. The company was founded in 2002 and is headquartered in Menlo Park, CA.

Wildcat Discovery Technologies, Inc. provides commercial research and development services. The firm engages in development projects for materials for other applications, including gas storage, carbon capture, thermoelectric, and structural materials. Its products include electrolyte additives such as EM1, CM1, CM2, and EM2. The company was founded by Peter G. Schultz and Robert K. Downs in 2006 and is headquartered in San Diego, CA.

Marcadia Biotech, Inc. develops therapeutic products for diabetes and obesity. It is a biopharmaceutical company focuses on developing a broad portfolio of drug candidates for treatment of diabetes and obesity. The company was founded in 2005 and is headquartered in Carmel, IN.

Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA.

Calibrium LLC develops biopharmaceuticals and diabetic drugs. The company is a biotech company that develops novel peptides that helps in the treatment of diabetes and related metabolic diseases. The company was founded by Fritz French and Richard DiMarch in 2013 and is headquartered in Carmel, IN.

Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA.

Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in San Rafael, California.

Bio*One Capital Pte Ltd (Bio*One Capital) is a venture capital subsidiary of EDB Investments Pte Ltd founded in 1991. The firm is headquartered in Singapore.

5AM Venture Management LLC (5AM Ventures) is an Independent Venture Capital firm founded in 2002 by Andrew J. Schwab, Carin M. Rollins and John D. Diekman. The firm is headquartered in San Francisco, US.

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award.

Envoy Therapeutics, Inc. manufactures and develops therapeutic drugs for neurological and psychiatric diseases. It was founded in 2009 and is headquartered in Jupiter, FL.

Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA.

Cellular Research, Inc. operates as a biotechnology research and development company. It offer Precise assays that provides quantitation of mRNA targets in single cells and small samples; precise predefined gene expression panels; and Pixel system, a detection platform for direct mRNA quantitation from single cells and rare samples. The company’s products are used in various applications that include gene expression validation, RNA-seq validation, pathway validation, and rare transcript detection. The company was founded by Stephen P. A. Fodor, Ari Chaney, Stephen R. Quake and Glenn Fu in 2011 and is headquartered in Menlo Park, CA.